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 Abstract 
A series of platinum(II) complexes bearing ∆4-1,2,4-oxadiazoline ligands have been 
synthesized and characterized. Their in vitro antitumor activity has been assessed in 
platinum sensitive and resistant human ovarian cancer cell lines (PEO1, PEOCisR, 
PEOCarboR and SK-OV3), as well as in colon cancer (SW948) and testicular cancer cell 
lines (N-TERA). All compounds tested showed potent cytotoxicity in the platinum sensitive 
cell lines, and retained activity in the cisplatin and carboplatin-resistant lines, with IC50 
values similar to the parental drug sensitive counterpart. We propose, therefore, that 
platinum(II) oxadiazoline complexes may possess a novel mechanism of action which 
render them active in tumor cells with resistance to currently used platinum anticancer 
agents. 
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 Introduction 
For a number of years platinum based chemotherapeutic regimens have been the mainstay 
for the management of epithelial ovarian cancer,1 testicular cancers, head and neck and a 
number of other solid tumor types.2 Cisplatin and carboplatin are frequently used in 
combination chemotherapy and their antitumor activity contributed significantly to the 
improvement in survival rates for patients with ovarian and testicular cancers when they 
were first introduced into the clinic. More recently, the platinum analogue oxaliplatin has 
been developed and is now licensed for use in metastatic colon cancer in the US.3 
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cisplatin        carboplatin    oxaliplatin 
Scheme 1. Platinum compounds currently used in cancer therapy 
 
However, in spite of their well-deserved place as main players in currently used 
chemotherapeutic regimens, resistance to platinum agents is a well-documented and 
unfortunate drawback in their use. In particular, the poor 5 year survival rates seen in 
epithelial ovarian cancer are at least partly attributed to the development of platinum 
resistance.4 Moreover, a large body of laboratory and clinically based evidence has sought 
to clarify and understand the molecular basis for platinum resistance in tumors.4-6  
Undoubtedly, a major aim of current anticancer drug development programs is to isolate 
and identify new compounds with the ability to overcome drug resistance, whilst still 
maintaining the potent antitumor activities of agents like cisplatin. 
In this context, trans-configured platinum compounds have found increasing interest, and a 
number of promising drug candidates could be identified.7 as for example Kelland’s Pt(IV) 
complexes bearing NH3 and aliphatic amines in trans position to each other.8 Farrell 
introduced mixed ligand PtCl2(L1)(L2) complexes where L1 and L2 can be both aromatic 
nitrogen heterocycles or one of the ligands can be ammine or a sulfoxide.9 Similarly, 
Navarro-Ranninger’s group successfully developed compounds bearing branched aliphatic 
amines as ligands,10 and Natile introduced imino-type ligands, which were synthesised in 
the coordination sphere of the ligand by addition of an alcohol to a coordinated nitrile,11a 
others by condensation of acetone with a platinum-ammine precursor.11b  
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Scheme 2. General strategy for the synthesis of platinum(II) oxadiazoline complexes. 
 
In the framework of our research, we now found an new class of trans-configured 
platinum(II) compounds whose in vitro properties suggest good potential for the 
development of new therapeutics that are able to overcome the resistance against 
conventionally used  platinum based antitumor agents: The modular synthetic strategy 
applied leads to structures with 4 to 7 sites of diversity and potentially lends itself for a 
combinatorial chemistry approach. The coordination sphere around the Pt (and thus the 
principal DNA interaction capacity) can be kept constant, while pharmacologically relevant 
parameters such as solubility, polarity, charge distribution, pK, logP or the transport 
properties can be addressed by the substitution pattern in the remote periphery of the 
complex. The heterocyclic ligands are designed to allow for additional interactions: e.g. 
aromatic substituents attached to the five membered ring could intercalate into the DNA and 
thus strengthen the interaction and circumvent repair mechanisms the Pt-resistant cells 
developed. Additionally, the ligand reactivity (e.g. N-O bond cleavage in a reducing 
environment) could cause secondary DNA damage. In oxygen-deficient cancer tissues this 
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could offer an additional reaction pathway that takes place in cancer cells but less so in 
normal cells. It has also been shown that the synthetic strategy can be extended to analogous 
Pt(IV) compounds12 and Pt(II) compounds bearing other ligands such as sulfoxides,13 so 
there is future scope for further optimization of the new lead structure. 
Results and Discussion 
 Synthesis and characterization of the platinum compounds 
The synthesis of the platinum(II) mono-oxadiazoline and platinum(II) bis-oxadiazoline 
complexes was achieved by cycloaddition of nitrones to PtCl2(nitrile)2 compounds, as 
shown in Scheme 2. The structure of the compounds prepared is shown in Scheme 3, 
together with the compound numbering. 
 
Scheme 3. Structures of the compounds prepared, together with the compound numbering.   
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The bis-nitrile complexes [PtCl2(PhCN)2], 1 and 2 were synthesized by ligand exchange, 
starting from cis/trans-[PtCl2(MeCN)2]. At the elevated temperatures applied in the 
synthesis the trans-isomers formed almost exclusively. In the case of [PtCl2(PhCN)2] and 2 
the pure trans compounds were obtained after chromatography. 1 formed in a trans:cis ratio 
of 95:5 and was used for subsequent reactions without further purification. Evidence for the 
structure was obtained from the IR spectra that display a C≡N stretching vibration in the 
typical range of N-coordinated aromatic nitriles, at 2287 to 2291 cm−1. Both elemental 
analysis and the mass spectrum confirm the elemental composition, and the 1H and 13C 
NMR spectra show the expected signal pattern of the N-coordinated nitriles. The 1H NMR 
of 1 displayed a second signal set of about 5% of the intensity of the major ones, revealing 
the presence of the cis-isomer. The 195Pt NMR spectra consist of one signal at –2350 
([PtCl2(PhCN)2]), −2339 (1) or –2313 ppm (2). This range is consistent with literature 
values for the trans-isomers of this type of complexes.14,15 The 195Pt NMR spectrum of 1 
shows an additional small peak at –2244 ppm for the cis-isomer. This compares well with 
the signal of the known cis-[PtCl2(p-MeO-C6H4CN)2] at –2239 ppm.14 
[PtCl2(PhCN)2] and 2 reacted with one equivalent of nitrone at room temperature to form 
the mono-cycloadducts 3 and 6 selectively. Elemental analysis and mass spectra are 
consistent with the proposed structure. The IR spectra show signals for the stretching 
vibration of the nitrile C≡N bond (2281 to 2288 cm−1) and the C=N bond of the 
oxadiazoline (1596 to 1603 cm−1), indicating that both ligands are present in the complex. 
Also the 1H and 13C NMR spectra consist of the signal patterns of both ligands, the nitrile 
and the oxadiazoline. The most characteristic 1H NMR signals for the oxadiazoline are the 
NMe peak at 3.02 to 3.05 ppm, and the N-CH-N appears as a broad singlet at 5.89 to 5.94 
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ppm. The ortho protons of the aromatic ring attached to the imino carbon of the 
oxadiazoline are strongly deshielded and shifted to high ppm values (8.98 to 9.04 ppm) due 
to their close proximity to the platinum center. In the 13C NMR spectrum the oxadiazoline 
can be recognized by the signal of the NMe group at 46.0 to 46.8 ppm, the N-CH-N group 
at 94.7 to 94.8 ppm, and the C=N functionality at 163.1 to 163.2 ppm. The 195Pt NMR 
signal is seen at –2216 ppm (6) and –2220 ppm (3). These values again compare well with 
those observed previously for similar complexes of this type.15,16 However, the 195Pt NMR 
data in this case are of little use for an assignment of the stereochemistry of the complex, 
because the signals of the cis and trans complexes are known to differ by 10 ppm only.15,16 
Our previous work has shown that ortho protons of the coordinated nitrile report most 
sensitively about the coordination geometry. In the cis complex, these protons are shielded 
from the magnetic field and the signals are shifted to low ppm values (7.17 for PhCN 
compared to 7.68 ppm in the trans complex or 7.60 ppm in the uncoordinated nitrile).15 In 
both 3 and 6 no such shielding is observed and the respective protons appear at similar ppm 
values as the free nitriles, in agreement of a proposed trans geometry of these complexes. It 
was also shown previously that cis-PtCl2(nitrile)(oxadiazoline) complexes can be prepared, 
but this requires the use of cis-PtCl2(nitrile)2 as a precursor, and the resulting complexes are 
not stable and decompose readily in solution.15 Finally, the synthesis of the mono-
oxadiazoline complex derived from 1 was attempted but not successful. Due to the poor 
solubility of 1 the cycloaddition is significantly less selective and only mixtures of mono- 
and bis-oxadiazoline complexes were obtained.  
The bis-oxadiazoline complexes 4, 5 and 7 are formed upon reaction of the bis-nitrile 
complexes [PtCl2(PhCN)2], 1 and 2 with two equivalents of the corresponding nitrone, at 
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elevated temperature and prolonged reaction times. Again, elemental analyses and mass 
spectra confirm the molecular formula. In the IR spectra the signal of the C≡N stretch has 
disappeared and a C=N stretching vibration is present at 1607 to 1604 cm−1. The 1H and 13C 
NMR spectra show signals of the oxadiazoline ligands only and compare well with data of 
similar trans-[PtCl2(oxadiazoline)2] complexes reported previously.15-17 Also the 195Pt 
resonance signals at –2028 to –2114 ppm agree well with expected values.15-17 There are 
two signals because of the existence of the bis-oxadiazoline complexes as diastereomers 
(meso-R,S form and racemic R,R/S,S form), due to the presence of a chiral carbon atom in 
position 3 of each of the oxadiazoline rings. These could not be separated and the isomeric 
mixtures were used for the assays. 
Solubility and stability studies 
The solubility of 4, 5 and 7 was investigated gravimetrically in distilled water, and 
compared with the solubility in phosphate buffered saline and isotonic saline (0.9g/ml) by 
UV spectroscopy. The solubility of all compounds was found to be similar and in an order 
of 0.5 to 4 mg/ml. The solubilities are thus comparable to the one of cisplatin of 1 mg/ml.18 
Since DMSO has been used for the preparation of stock solutions, the stability of 1 - 7 in d6-
DMSO was studied using 1H and 195Pt NMR spectroscopy. The bis-oxadiazoline complexes 
4, 5 and 6 were stable during incubation at 25 oC over 10 weeks, and even for 10 days at 60 
oC before first signs of degradation became apparent in the 1H NMR spectrum. No new 
signal indicative of DMSO coordinated species could be detected in the 195Pt NMR. 
Therefore handling and storage of stock solutions should not pose any problems. The mono-
oxadiazoline complexes 3 and 6, however, exhibit a significantly higher reactivity towards 
DMSO. Within 3 h at 25 oC there was 70% conversion and exchange of the remaining 
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nitrile ligand by DMSO had taken place. The newly formed platinum compounds were 
isolated and identified as the complexes cis- and trans-[PtCl2(d6-DMSO)(oxadiazoline)] 
(dichloro[2,3-dihydro-2-methyl-3-“R”-5-“R’”-1,2,4-oxadiazole-κN4][(sulfinyl-κS)bis 
[methane]]platinum) by 1H, 13C and 195Pt NMR spectroscopy and comparison of the data 
with literature values of the parent compound lacking the OH or glycol group.8 The bis-
nitrile complexes 1 and 2 are very prone to ligand exchange in DMSO. Complete 
conversion into the known complex [PtCl2(DMSO)2] (dichlorobis[(sulfinyl-
κS)bis[methane]]platinum) takes place at 25 oC within 2 h. Consequently, the bis-nitrile 
complexes have not been used for cytotoxicity testing. 
1H NMR was also used to study the stability of 5 in an aqueous medium. Since the 
solubility of 5 in water or saline is not sufficiently high, NMR experiments were performed 
in d6-acetone/H2O 9:1 and in d6-acetone/H2O/Na2CO3. Although these experiments did not 
reveal whether hydrolysis of one or more of the chloro ligands plays any role, we were able 
to establish that the oxadiazoline ligands in 5 are stable over 10 d at 40 oC, in both neutral 
and alkaline medium. The alkaline medium was used with the idea in mind that the phenolic 
OH group can be deprotonated quite easily and this could alter the solubility, the chemical 
and pharmacological properties of the platinum complex.  
In vitro activities 
The in vitro antiproliferative activity of the compounds was determined by means of a 
colorimetric microculture assay technique (MTT assay), as described in the experimental 
section. Typically, the data shown indicate the somewhat higher potency that cisplatin has 
over carboplatin, which is a repeatable finding throughout the literature. Apart from 7, the 
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compounds in this study showed comparable, and against SW948 even superior activity in 
comparison with the reference compound cisplatin. 
Importantly, against platinum-resistant cell lines the activity of 5 is essentially retained. The 
same holds true for 4 and 5 when tested in PEO1cisR, but 4 is less active against the 
PEO1carboR whereas 6 becomes even more active. 5 is comparable to cisplatin in potency 
being slightly less potent in PEO1 cells but more potent against the colon cancer cell line 
SW948. 7 is similar in potency to carboplatin, 6 and 4 occupy an intermediate position. 
Importantly, 6 appears to be more active in the PEO1CarboR cell line that in the parental 
cell line. 
Table 1. Antiproliferative activity of platinum agents in platinum-sensitive and resistant 
tumor cell line models.  
CELL LINE cisplatin carboplatin 4 5 6 7 
 
PEO1 
Ovarian 
cancer 
 
 
1.34 (0.82) 
 
32.6 (11.6) 
 
16.6 (3.4) 
 
8.7 (3.0) 
 
16.3 (3.3) 
 
39.6 (19.3) 
 
PEO1CisR 
(cisplatin 
resistant) 
 
 
5.1 (1.4) 
 
138 
 
15.6 (1.9) 
 
6.9 (0.92) 
 
11.2 (5.3) 
 
nd 
 
PEO1carboR 
(carboplatin 
resistant) 
 
 
6.3 (2.6) 
 
130.7 (43.5) 
 
25.5 (13.4) 
 
8.9 (4.9) 
 
5.2 (1.8) 
 
43.6 (15.4) 
 
SK-OV3 
Ovarian 
cancer 
 
 
13.1 (2.1) 
 
92.8 (6.1) 
 
32.3 (3.7) 
 
10.4 (3.2) 
 
35.8 (5.0) 
 
>100 
 
SW948 
Colon cancer 
 
 
44.8 (13.3) 
 
nd 
 
29.4 (4.30) 
 
9.6 (1.9) 
 
22.3 (8.9) 
 
nd 
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N-TERA 
Testicular 
cancer 
 
0.78 (0.27) nd 7.3 (0.7) 1.95 (0.9) 6.1 (0.6) >100 
Footnote: Data shown are IC 50 values (µM), all data are mean values of >3 repeat assays, 
the standard deviation is given in parenthesis. 
nd = not determined 
 
Overall, for different cancer cell lines and also for the Pt-resistant ones, the following trends 
can be seen: 5 has highest potency, followed by 6 and 4, and finally 7 the least active 
compound. We consistently saw lower IC50 values for the test compounds in SW948 colon 
cancer cells than the value for the reference compound cisplatin. There is a large differential 
between the activities of 7 versus 6. Hence we may conclude at this stage that a mono-
oxadiazoline complex is more active than the bis-oxadiazoline substituted one. Comparing 4 
and 5, there is a consistent finding that 5 is significantly more potent than 4, although these 
two compounds are isomers of each other, differing in the position of an OH group only. 
Cisplatin and carboplatin were made up as stock solutions in sterile aqueous 0.9% w/v NaCl 
(saline solution) and diluted in tissue culture medium to give the required final 
concentrations for the MTT assay. Compounds 4 – 7 were generally used as stock solutions 
made up in DMSO and then subjected to further dilution as for cisplatin and carboplatin. 
We also used 4 as an aqueous stock solution and found that there was no significant 
variation in the cytotoxicity testing when compared with a DMSO stock solution. 
Cell cycle analysis 
For the PEO1 parental cells the cell cycle perturbation we saw following a 48h incubation 
with 2.5µM cisplatin is a characteristic G2M blockade of the cell cycle, relative to control 
untreated cells (see Figure 1). The effect of cisplatin in the carboplatin resistant 
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PEO1CarboR line gave rise to a more modest G2M block, consistent with its drug resistant 
phenotype. These data are in contrast with those obtained with our most potent compound 5 
where we failed to see any marked cell cycle blockade. However, there was evidence of a 
small G1 accumulation together with a build up of cells in the sub-G1 phase, which is 
indicative of early apoptosis. The results were similar to the effects seen with 24 h 
incubation and were similar for both cell lines, with a larger sub-G1 phase being seen for 
PEO1CarboR. 
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Figure 1. 
 Concluding Remarks. 
The development of platinum analogues remains an active area of medicinal chemistry.  To 
date, over 30 platinum complexes have entered clinical trials worldwide in an effort to 
circumvent side-effects and resistance shown to cisplatin. In the present study we show that 
platinum(II) oxadiazoline substituted complexes are capable of overcoming platinum 
resistance. The clinical problem of platinum-refractory disease is highlighted by the poor 
responses of advanced/late stage ovarian cancer to carboplatin or cisplatin containing 
regimes. Like us, other groups have focused their efforts on the identification of novel 
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platinum structures that may offer improved properties over those agents currently 
available. For example, Yu et al.19 have described the anticancer activity of a series of 
platinum complexes that possess a demethylcantharidin moiety, shown to overcome 
platinum resistance in tumour cell lines models. Kalinowska et al.20 have studied analogues 
of trans-platinum(II) containing two diethyl (pyridin-4-ylmethyl) phosphates which show 
IC50 values in a similar range to cisplatin in tumour cell lines, also seen for our study. 
Two new potential lead structures have been established, both of which exhibit a potency 
similar to carboplatin or better, for most cell lines studied.  The activity is retained in 
cisplatin and carboplatin resistant cell lines. The bis-oxadiazoline complexes appear to 
perform better with respect to stability. The high activity of compounds 5 and 6 relative to 
cisplatin may relate to many features of the compounds interactions on a cellular level. The 
finding of activity of trans platinum compounds in cancer cells with resistance to cis 
platinum compounds (such as cisplatin) has been reported by others.21 We plan to evaluate 
in vivo activity of compounds 5 and 6 in platinum resistant ovarian cancer xenograft 
models. The effects of platinum compounds on cell cycle has been looked at in some detail 
by others22 and can provide valuable information on the mechanism of action of platinum 
based cytotoxic compounds. Of great interest are our preliminary experiments that have 
addressed the issue of cell cycle blockade. Whilst cisplatin predictably gave rise to a G2M 
blockade as seen by others,23 we were unable to see significant changes in cell cycle apart 
from a slight accumulation of sub-G1 and G1 when cells were treated with compound 5 
under the same experimental conditions. This is in contrast to the findings of others who 
have looked at the effects of trans platinum compounds22 and see prolonged S-phase and 
G2M phase arrest. They have studied these effects over a more prolonged time period than 
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in the current study i.e. 24-96 h time points as opposed to the 24 h and 48 h time points we 
used. It may well be that cell cycle perturbations due to treatment with compound 5 will be 
manifest if we look at longer treatment times. However, our data provide prima facie 
evidence that the oxadiazoline containing trans platinum compounds differ from cisplatin 
and carboplatin in their cell cycle effects. Our studies are currently ongoing to elucidate the 
cell cycle blockade effects of the oxadiazoline trans platinum compounds used in the 
present study. 
 Experimental Section  
 Materials and Instrumentation. Solvents and reagents for synthesis were obtained 
from commercial sources and used as received. Cis/trans-[PtCl2(MeCN)2],24,25 trans-
[PtCl2(PhCN)2],26,27 4-(2-methoxyethoxy)benzonitrile28 and nitrones29,30 were prepared 
according to published methods. The synthesis and spectroscopic characterization of the 
new compounds 1 and 2 is described in the Supporting Information. C, H and N elemental 
analyses were carried out on a Leeman CE 440 automatic analyzer.  Infrared spectra (4000-
400 cm−1) were recorded on Perkin Elmer 2000 FTIR and Nicolet Avatar 320 FT-IR 
spectrometers in KBr pellets. Positive FAB-MS spectra of the samples in 3-nitrobenzyl 
alcohol (NBA) matrices were obtained on a Thermoquest MAT 95XL instrument. 1H, 13C 
and 195Pt NMR experiments were acquired on a Bruker DRX 500 spectrometer at ambient 
temperature. Signals in 1H and 13C were assigned with the help of COSY, NOESY and 
HMQC spectra. 195Pt chemical shifts are given relative to aqueous K2[PtCl4] = −1630 ppm, 
with half height line widths in parenthesis.  
Preparation of the trans-[PtCl2(nitrile)(oxadiazoline)] complexes. 
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Trans-[PtCl2(PhCN){N=C(Ph)-O-N(Me)-CH(p-HO-C6H4)}], trans-(benzonitrile)-
dichloro[2,3-dihydro-3-(4-hydroxyphenyl)-2-methyl-5-phenyl-1,2,4-oxadiazole-
κN4]platinum (3). A mixture of trans-[PtCl2(PhCN)2] (47.2 mg, 0.1 mmol) and C-(p-
hydroxyphenyl)-N-methylnitrone (15.1 mg, 0.1 mmol) in CHCl3 (1 ml) was stirred for 3 
days at 25oC under nitrogen atmosphere. The reaction was monitored periodically by 1H 
NMR and stopped at the first appearance of signals of the bis(oxadiazoline) complex. The 
product was purified by chromatography on SiO2 using firstly CH2Cl2 to remove unreacted 
trans-[PtCl2(PhCN)2], then CH2Cl2/ethyl acetate 10/1 to elute the platinum oxadiazoline 
complex. Yellow crystalline solid, yield 71%. Anal. (C22H19Cl2N3O2Pt) C, H, N. FAB+-MS, 
m/z: 624 [M + H]+, 646 [M + Na]+ , 587.0 [M − HCl], 551 [M − 2HCl], 521 [M − PhCN]. 
IR spectrum (KBr), selected bands, cm−1: 2288 ν(C≡N), 1596 ν(C=N). 1H NMR (500 MHz, 
d6-acetone) δ(ppm): 3.02 (s, 3H, NMe), 5.89 (s, 1H, NCHN), 8.57 (s, H, OH), 8.98 (d, 8.0 
Hz, 2H), 7.69 (m, 2H) and 7.85 (t, 7.0 Hz, 1H)(PhC=N), 7.53 (d, 8.5 Hz, 2H) and 6.90 (d, 
8.5Hz, 2H)( p-HO-C6H4), 7.69 (m, 2H), 7.81(m, 1H) and 7.92 (d, 7.2 Hz, 2H)(PhC≡N). 13C 
NMR (125.7 MHz, d6-acetone) δ(ppm): 46.0 (NMe), 94.8 (NCHN), 116.0 (C≡N), 130.6, 
130.7 and 128.6 (PhC=N, CH), 115.7 and 129.3  (p-HO-C6H4, CH), 134.7, 134.1 and 133.6 
(PhC≡N, CH), 109.7 (ArC(1)CN), 157.5 (ArC(4)-O), 163.1 (C=N), 122.3 (PhC≡N, Cq), 
132.4 (PhC=N, Cq). 195Pt NMR  (107.3 MHz, d6-acetone) δ(ppm): -2220 (1075 Hz).  
Trans-[PtCl2(p-MeOC2H4O-C6H4CN){N=C(p-MeOC2H4O-C6H4)-O-N(Me)-CH(Ph)}], 
trans-dichloro[4-(2-methoxyethoxy)benzonitrile][2,3-dihydro-5-(4-(2-methoxy 
ethoxy)phenyl)-2-methyl-3-phenyl-1,2,4-oxadiazole-κN4]platinum (6). This compound 
was prepared by reaction of [PtCl2(p-MeOC2H4O-C6H4CN)2] with phenyl-N-methyl-
nitrone, using the reaction protocol above. The reaction time was 7 days, and CH2Cl2/ethyl 
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acetate 4/1 was used as eluent for the chromatographic purification of the complex. Pale 
yellow solid, yield 67%. Anal. (C28H31Cl2N3O5Pt) C, H, N. FAB+-MS, m/z: 756 [M + H]+, 
778 [M + Na], 719 [M − HCl], 683 [M − 2HCl]. IR spectrum (KBr), selected bands, cm−1: 
2281 ν(C≡N), 1603 ν(C=N). 1H NMR (500 MHz, CDCl3) δ(ppm): 3.05 (s, 3H, NMe), 3.77 
(m, 4H, CH2-O), 4.20 (m, 4H, O-CH2), 3.46 (s, 6H, MeO), 5.94 (s, 1H, NCHN), 6.98 (d, 8.5 
Hz, 2H) and 7.63 (d, 5.8 Hz, 2H)(R-C6H4C≡N), 7.09 (d, 8.5 Hz, 2H) and 9.04 (d, 8.5 Hz, 
2H)(N=C-C6H4-R), 7.45 (m, 3H) and 7.70 (d, 6.8 Hz, 2H)(Ph). 13C NMR (125.7 MHz, 
CDCl3) δ(ppm): 46.8 (NMe), 59.5 (OMe), 67.9 (CH2-O), 70.8 (O-CH2), 94.7 (NCHN), 
117.2 (C≡N), 115.5 and 135.5 (R-C6H4C≡N, CH), 101.3 and 163.7 (R-C6H4C≡N, Cq), 114.6 
and 133.1 (N=C-C6H4-R, CH), 128.9 and 163.9 (N=C-C6H4-R, Cq), 128.7, 128.6 and 129.9 
(Ph, CH), 134.2 (Ph, Cq), 163.2 (C=N). 195Pt NMR  (107.3 MHz, CDCl3) δ(ppm): -2216 
(790 Hz). 
Preparation of the trans-[PtCl2(oxadiazoline)2] complexes. 
Trans-[PtCl2{N=C(Ph)-O-N(Me)-CH(p-HO-C6H4)}2], trans-dichlorobis[2,3-dihydro-3-
(4-hydroxyphenyl)-2-methyl-5-phenyl-1,2,4-oxadiazole-κN4]platinum (4). Trans-
PtCl2(PhCN)2 (47.2 mg, 0.1mmol) and C-(p-hydroxyphenyl)-N-methyl-nitrone (33.2 mg, 
0.22 mmol) were dissolved in a 1:1 mixture of acetone and CHCl3 (1 ml). The reaction 
mixture was stirred at 50oC for 7 days. The product was isolated by filtration and washed 
with ether. A second crop of product was recovered from the remaining solution by 
chromatography (SiO2, CH2Cl2/ethyl acetate 4/1). 
Pale yellow solid, overall yield 48%, two diastereomers 4a:4b = 70:30. Anal. 
(C30H28Cl2N4O4Pt) C, H, N. FAB+-MS, m/z: 797 [M + Na]+, 775 [M]+, 737 [M – HCl]+, 702 
[M – 2HCl]+. IR spectrum (KBr), selected bands, cm−1: 1604 ν(C=N). 1H NMR (500 MHz, 
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d6-DMSO) δ(ppm): 2.88 (s, 3H, NMe), 5.86 (s, 1H, NCH), 6.84 (d, 8.6 Hz, 2H) and 7.41 (d, 
8.6 Hz, 2H)(p-HO-C6H4), 7.57 (t, 8.0 Hz, 2H), 7.81 (t, 8.0 Hz, 1H) and 8.74 (d, 8.0 Hz, 
2H)(Ph), 9.69 (s, 1H, OH). 13C NMR (125.7 MHz, d6-DMSO) δ(ppm): 45.5 (NMe), 93.6 
(NCHN), 114.9 and 129.8 (p-HO-C6H4, CH), 158.3  (p-HO-C6H4, Cq), 133.8, 128.4 and 
129.9 (Ph, CH), 121.9 (Ph, Cq), 162.5(C=N). 195Pt NMR (107.3 MHz, d6-acetone) δ(ppm): -
2115 and -2122 (1075 Hz).  
Trans-[PtCl2{N=C(p-HO-C6H4)-O-N(Me)-CH(Ph)}2], trans-dichlorobis[2,3-dihydro-5-
(4-hydroxyphenyl)-2-methyl-3-phenyl-1,2,4-oxadiazole-κN4]platinum (5). This 
compound was prepared by reaction of [PtCl2(p-HO-C6H4CN)2] with C-phenyl-N-methyl-
nitrone using the reaction protocol above, with acetone as a solvent. The product was 
isolated by evaporation of most of the solvent and precipitation with diethyl ether.  
Yellow cream solid, yield 55%, two diastereoisomers 5a:5b = 55/45. Anal. 
(C30H28Cl2N4O4Pt) C, H, N. FAB+-MS, m/z: 814 [M + K]+, 798 [M + Na]+, 775 [M]+ , 704 
[M – 2HCl]+. IR spectrum (KBr), selected bands, cm−1: 1607 ν(C=N). 1H NMR (500 MHz, 
d6-acetone) δ(ppm): 5a: 2.94 (s, br., 3H, NMe), 5.92 (s, br., 1H, NCH), 6.88 (d, 8.5Hz, 2H) 
and 8.82 (“d”, br., 2H)(p-HO-C6H4), 7.45 (m, br., 3H) and 7.60 (m, br., 2H)(Ph), 9.50 (s, 
1H, OH). 5b: 2.95 (s, br., 3H, NMe), 5.95 (s, br., 1H, NCH), 7.00 (“d”, br., 2H) and 8.78 
(“d”, br., 2H)(p-HO-C6H4), 7.43 (m, br., 3H) and 7.66 (m, br., 2H)(Ph), 9.50 (s, 1H, OH). 
13C NMR (125.7 MHz, d6-acetone, 10% D2O, Na2CO3) δ(ppm): 5a and 5b: 45.6 (NMe), 
94.2 (NCHN), 119.6 and 133.3 / 133.4 (p-HO-C6H4, CH), 104.3 and 163.3 / 164.3 (p-HO-
C6H4, Cq), 128.5, 128.6 and 129.0 (Ph, CH). The quaternary carbons of the Ph and the C=N 
group have not been detected. 195Pt NMR (107.3 MHz, d6-acetone) δ(ppm): 5a and 5b: -
2028 and -2049 (1075 Hz). 
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Trans-[PtCl2{N=C(p-MeO-C2H4O-C6H4)-O-N(Me)-CH(Ph)}2], trans-dichlorobis-[2,3-
dihydro-5-(4-(2-methoxyethoxy)phenyl)-2-methyl-3-phenyl-1,2,4-oxadiazole-κN4] 
platinum (7). This compound was prepared by reaction of [PtCl2(p-MeO-C2H4O-
C6H4CN)2] with C-phenyl-N-methyl-nitrone using the reaction protocol above. CHCl3 was 
used as solvent, and the reaction was complete after 7 d at 50oC. The solvent was 
evaporated under vacuum and the residue purified by chromatography on silica using 
CH2Cl2/ethyl acetate 4:1 as eluent. 
Yellow-brown solid, yield 45%, two diastereoisomers 7a:7b = 50/50. Anal. 
(C36H40Cl2N4O6Pt) C, H, N. FAB+-MS, m/z: 913 [M + Na]+, 891 [M]+, 854. [M – HCl]+, 
817 [M – 2HCl]+. IR spectrum (KBr), selected bands, cm−1: 1605 ν(C=N). 1H NMR (500 
MHz, CDCl3) δ(ppm): 7a:7b = 50/50: 2.91 / 2.94 (s, 3H, NMe), 3.79 (m, 2H, CH2-O), 4.19 
(m, 2H, O-CH2), 3.47 (m, 3H, MeO),  5.88 (s, 1H, NCH), 7.48 (m, 3H) and 7.60 (m, 
2H)(Ph), 6.82 (m, 2H) and 8.66 (d, 8.5 Hz, 2H of 7b) / 8.82 (m, br., 2H of 7a)(p-R-C6H4). 
13C NMR (125.7 MHz, CDCl3) δ(ppm): 46.3 (NMe), 59.3 (OMe), 67.6 (CH2-O), 70.8 (O-
CH2), 94.7 (NCHN), 128.5, 128.6 and 129.5 (Ph, CH), 136.5 (Ph, Cq), 114.3 and 132.7 / 
133.0 (p-R-C6H4, CH), 128.9 and 162.9 (p-R-C6H4, Cq), 163.0 (C=N). 195Pt NMR (107.3 
MHz, CDCl3) δ(ppm): -2107 (775 Hz) and -2124, 2 (775 Hz). 
 
Cell culture. 
All tissue culture reagents were obtained from Sigma Aldrich (Poole, UK), unless stated 
otherwise. The PEO1 ovarian cancer cell line was originally developed by Langdon et al. 
and obtained from Prof F. Balkwill (formerly of ICRF laboratories, Lincoln Inn Fields, 
London, UK). The PEO1CisR (cisplatin resistant) and PEO1CarboR (carboplatin resistant) 
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cell lines were derived in-house and possess approximately 5- fold resistance to their 
respective inducing agent. All PEO1 cell lines were cultured in RPMI-1640 medium 
supplemented with 10% foetal calf serum (heat inactivated, obtained from Invitrogen, 
Paisley, UK) and 2 mM Glutamax (Invitrogen) as monolayers.  
SK-OV-3 human ovarian adenocarcinoma cell line was obtained from the European 
Collection of Cell Cultures (Salisbury, UK) and cultured in Dulbecco’s Modified Eagle’s 
Medium (DMEM) with supplements as above. The NTERA-2 cell line is described as an 
embryonal human testicular carcinoma cell line and was obtained from ATCC (LGC 
Promochem, Teddington, UK). This cell line was cultured in Dulbecco’s Modified Eagle’s 
Medium with 4 mM glutamine and 10% foetal calf serum. SW-948 is a colonic 
adenocarcinoma cell line established from a grade III adenocarcinoma of the colon and was 
obtained from ATCC. The culture medium was L-15 medium supplemented with 2 mM 
glutamine and 10% foetal calf serum. All cell lines were grown as attached monolayers 
which were removed by treatment with trypsin-EDTA solution to produce a single cell 
suspension for use in chemosensitivity testing. 
Cytotoxicity Testing.  
Cytotoxicity was determined by means of the colorimetric assay MTT (3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide). Cultured cell monolayers were 
reduced to a single cell suspension (as described above) and then seeded into 96-well tissue 
culture plates at a density of 6 x 103 cells per well for all cell lines, apart from N-TERA-2 
which were seeded at a density of 1 x 104 cells per well. This was calculated to allow for 
exponential growth of the cultures throughout the incubation period. Cells were allowed to 
settle for 24 h, under standard culture incubation conditions and then drug treated with a 
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dose range spanning 2-logs of drug concentration, each drug aliquot being administered in a 
50 µl volume. All drug dilutions were carried out in complete culture medium. After 72 h 
incubation under standard culture conditions MTT solution (5 mg/ml in PBS) was added in 
a 20 µl volume and incubated for a further 4 h. The MTT/medium mixture was then 
removed and the resulting formazan crystals dissolved in 200 µl of DMSO. The optical 
density of the purple color product was measured at 550 nm in a plate reading 
spectrophotometer. The quantity of live cells was expressed as T/C values by comparison 
with untreated control microcultures. The concentration of complexes that decreased 
absorption by 50% were calculated by interpolation and expressed as IC50 values. 
Cell Cycle analysis using Propidium Iodide: PEO1 human ovarian cancer cells at a 
density of 4 × 104 cells/ml were left to adhere in flasks for 4-6h.  Cells were treated with 
drug at approximately twice the IC50 dose (obtained from the MTT assay data with a 
continuous exposure over 72h). Cells were harvested at 48h and washed in PBS before 
resuspension in 70% ethanol in PBS, added whilst vortex mixing and left at 4°C for at least 
24h.  After washing in PBS, cells were stained in 10µg/ml propidium iodide (Sigma) and 
1mg/ml ribonuclease A (Sigma) for at least 30mins at 37°C in the dark.  Fluorescence 
>575nm versus light scatter was measured with excitation of 488nm on a Beckman-Coulter 
Epics-XL .Data shown on each histogram are representative of >3 separate experiments 
with typical results obtained shown in the figure. 
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FIGURE CAPTIONS AND SCHEME TITLES  
 
 
 
Scheme 1 Platinum compounds currently used in cancer therapy.   
 
Scheme 2 General strategy for the synthesis of platinum(II) oxadiazoline complexes.  
 
Scheme 3 Structures of the compounds prepared, together with the compound 
numbering.   
 
Figure 1 Bar chart showing effects of platinum agents on cell cycle in PEO1 human 
ovarian cancer cells. Data shown are the mean of >3 replicate analyses with 
the standard deviation shown as error bars. 
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